Exparel for Rotator Cuff Surgery
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug Exparel for rotator cuff surgery?
Research suggests that liposomal bupivacaine, the active ingredient in Exparel, may help reduce postoperative pain and decrease the need for narcotics after rotator cuff surgery. Studies have shown that it can provide longer-lasting pain relief compared to conventional bupivacaine, especially when used in combination with other medications like dexamethasone.12345
Is Exparel (liposomal bupivacaine) safe for use in humans?
Exparel, a form of liposomal bupivacaine, is generally considered safe for use in humans and has been approved by the FDA for pain relief in various surgeries, including breast augmentation and shoulder surgeries. However, it can have side effects that may lead to emergency department visits, especially when used in certain types of nerve blocks for shoulder surgery.12367
How is the drug Exparel different from other treatments for rotator cuff surgery?
Exparel is unique because it is a long-acting local anesthetic that uses a special liposomal formulation to release bupivacaine slowly over time, providing extended pain relief after surgery. This is different from standard treatments that may require more frequent dosing or have shorter durations of action.13689
What is the purpose of this trial?
The goal of this clinical trial is to investigate if there is a difference in pain after an arthroscopic rotator cuff surgery when a nerve block is performed with liposomal bupivacaine versus the standard treatment of bupivacaine alone.The main question aims to answer if patients who receive liposomal bupivacaine have better pain control and lower postoperative opioid consumption compared to bupivacaine alone.Participants be randomized to either the control group to receive a standard interscalene block with bupivacaine (25 cc of bupivacaine) or the experimental group to receive similar dosing of liposomal bupivacaine mixed with bupivacaine (10cc liposomal bupivacaine + 15cc bupivacaine). Data will be prospectively collected and the data from the experimental group will be compared to the control group at the completion of the study period.
Research Team
Catherine J Fedorka, MD
Principal Investigator
The Cooper Health System
Eligibility Criteria
This trial is for adults over 18 who are having rotator cuff surgery and will receive an interscalene block. It's not for those unwilling to have this block, pregnant or nursing women, people with liver disease or severe lung conditions like COPD, or allergies to bupivacaine or liposomal bupivacaine.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either a standard interscalene block with bupivacaine or an interscalene block with Exparel solution during rotator cuff surgery
Postoperative Monitoring
Participants log their pain scores and narcotic consumption daily for 2 weeks post-surgery
Follow-up
Participants are monitored for pain severity and opioid consumption at 6 and 12 weeks post-surgery
Treatment Details
Interventions
- Bupivacaine
- Liposomal Bupivacaine
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Cooper Health System
Lead Sponsor